Article
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2014
Nishiguchi Shuhei, Sakai Yoshiyuki, Kuboki Makoto, Tsunematsu Satoshi, Urano Yasuhisa, Sakamoto Wataru, Tsuda Yasuhiro, Steinmann Gerhard, Omata Masao
Abstract excerpt
BACKGROUND & AIMS: Faldaprevir (BI 201335) is a potent once-daily (QD) NS3/4A protease inhibitor for the treatment of patients with genotype-1 (GT-1) hepatitis C virus (HCV). The aim of this study was to evaluate the safety, pharmacokinetics and efficacy of faldaprevir plus pegylated interferon a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
